In this on-demand multimedia module combining slides and audio from a live symposium presented at the 2016 annual meeting of the AASLD in Boston, Massachusetts, multidisciplinary expert faulty provide their perspectives on practical aspects of managing patients with HCV, including interpretation of current guidelines and payer policies, approaches to patient engagement in care, specialty pharmacy utilization and navigation of the insurance appeals process, and management of people who inject drugs.
Sherilyn C. Brinkley, MSN, CRNP, has disclosed that she has received funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck and consulting fees from AbbVie and Merck.
Jordan J. Feld, MD, MPH, has disclosed that he has received funds for research support from Abbott, AbbVie, Gilead Sciences, Janssen, Merck, and Regulus and consulting fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, and Merck.
Jason Grebely, BSc, PhD, has disclosed that he has received funds for research support from AbbVie, Cepheid, Gilead Sciences, and Merck; consulting fees from AbbVie, Gilead Sciences, and Merck; and fees for non-CME/CE services received directly from a commercial interest or their agents (eg, speaker bureaus) from AbbVie, Gilead Sciences, and Merck.
Nancy Reau, MD, FAASLD, AGAF, has disclosed that she has received funds for research support from AbbVie, Gilead Sciences, and Intercept and consulting fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck.
Phoebe Sebhatu, PharmD, BCPS, has disclosed that she has received consulting fees from Bristol-Myers Squibb.
Addressing Practical Challenges in HCV Management
How Recent Guideline Updates on HBV Screening in HCV-Infected DAA Recipients Affect Clinical Practice
Norah Terrault MD, MPH - 11/23/2016
1 comment / Last Comment: 11/29/2016
How do recent AASLD/IDSA updates on HBV screening change nonspecialist and specialist management of HCV patients? Here’s my take.
My Evolving Strategy for Treating Patients With Genotype 3 HCV Infection
Norah Terrault MD, MPH - 9/10/2015
10 comments / Last Comment: 6/25/2016
Following the recent FDA approval of daclatasvir and the presentation of key data at the 2015 EASL meeting, our team has made several changes to our approach in managing patients with genotype 3 HCV infection.
Weighing the Treatment Options for Genotype 3 HCV Infection in Cirrhotics
Mark S. Sulkowski MD - 2/25/2016
3 comments / Last Comment: 4/11/2016
In my practice, it is the patient with cirrhosis and genotype 3 HCV infection who causes me to pause and carefully consider the patient’s treatment options.
Decompensated Cirrhosis: My Take on New Treatment Strategies Following AASLD 2015
Ira M. Jacobson MD - 12/24/2015
2 comments / Last Comment: 1/4/2016
Despite the variety of highly effective, highly tolerable regimens available for treating HCV, strategies for patients with decompensated liver disease remain challenging.
How Data From the 2016 Boston Hepatology Meeting Will Influence Future HCV Patient Management
Mark S. Sulkowski MD - 1/31/2017
1 comment / Last Comment: 2/13/2017
The 2016 hepatology meeting in Boston offered future solutions to some of my most vexing patient challenges.